Therapy Areas: Oncology
Photocure maintains 2028 Medicare coverage target for AssureMDx following CMS update
9 November 2026 - Diagnostic company Photocure ASA (OSE: PHO) confirmed on Monday that the anticipated Medicare coverage timeline for its AssureMDx bladder cancer test remains aligned with its origina...
RYBREVANT FASPRO co-formulated with Halozyme's ENHANZE technology approved by US FDA in advanced head and neck cancer
9 November 2026 - Biotechnology company Halozyme Therapeutics Inc (Nasdaq:HALO) announced on Friday that Johnson & Johnson (NYSE:JNJ) was granted accelerated approval from the US Food and Drug Adm...
Akeso publishes ivonescimab Phase II study results in Nature Medicine
6 November 2026 - Chinese pharmaceutical company Akeso Inc (HKEX:9926) announced on Thursday that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific antibody ivo...
INOVIO prices public offering of approximately USD75m
6 November 2026 - INOVIO Pharmaceuticals Inc (Nasdaq:INO), a biotechnology company focused on developing and commercialising DNA medicines to help treat and protect people from HPV-related diseases, c...
First patient dosed in Phase 1 trial of Transgene and BioInvent's BT-001 for rectal cancer
5 November 2026 - French biotech company Transgene (Euronext Paris:TNG) and the University of Copenhagen have dosed the first patient in the Phase 1 OV-PRIME-R trial evaluating BT-001 in patients with...
Elicera Therapeutics secures Chinese patent allowance for ELC-401
5 November 2026 - Swedish clinical stage immuno-oncology company Elicera Therapeutics AB (STO: ELIC) on Thursday said the China National Intellectual Property Administration has issued a notice of all...